Core Insights - West Pharmaceutical Services, Inc. (WST) reported adjusted fourth-quarter 2025 earnings per share (EPS) of $2.04, a 12.1% increase year over year, exceeding the Zacks Consensus Estimate by 11.5% [1] - The company achieved revenues of $805 million in the fourth quarter, reflecting a 7.5% year-over-year growth, surpassing the Zacks Consensus Estimate by 1.4% [2] - Full-year 2025 revenues reached $3.07 billion, marking a 6.3% increase from 2024, with organic revenues up 4.3% year over year [3] Financial Performance - Adjusted EPS for the full year was $7.29, an 8% increase from 2024 [1] - GAAP EPS for the fourth quarter was $1.82, a 2.2% improvement from the previous year [1] - Gross profit for the quarter increased by 11.1% to $303.9 million, with a gross margin expansion of 130 basis points to 37.8% [10] Segment Performance - Proprietary Products segment reported revenues of $661.8 million, up 7.8% year over year, with high-value products accounting for 48% of net sales [7][8] - Contract-Manufactured Products segment revenues totaled $143.2 million, reflecting a 6.2% year-over-year increase [9] Guidance and Outlook - For Q1 2026, WST expects sales between $770 million and $790 million, with EPS projected in the range of $1.65-$1.70 [14] - Full-year 2026 revenues are anticipated to be between $3.21 billion and $3.27 billion, with organic net sales expected to grow 5-7% [15] - Adjusted EPS for 2026 is projected to be in the range of $7.85-$8.20 [16] Strategic Insights - The company attributes its strong performance to consistent execution of its growth strategy, particularly in the high-value product segment [18] - Management expects the momentum to continue into 2026, focusing on operational discipline and growth sustainability [18] - The guidance reflects steady demand fundamentals and favorable currency tailwinds [19]

Core Insights - West Pharmaceutical Services (WST) reported revenue of $805 million for the quarter ended December 2025, reflecting a year-over-year increase of 7.5% and surpassing the Zacks Consensus Estimate by 1.35% [1] - The company's EPS for the quarter was $2.04, up from $1.82 in the same quarter last year, resulting in an EPS surprise of 11.21% compared to the consensus estimate of $1.83 [1] Financial Performance Metrics - Organic revenue growth was reported at 3.3%, exceeding the average analyst estimate of 1.8% [4] - Net sales from contract-manufactured products reached $143.2 million, slightly below the average estimate of $144.45 million, but showing a year-over-year increase of 6.2% [4] - Net sales from proprietary products amounted to $661.8 million, surpassing the average estimate of $648.56 million and representing a 7.8% increase compared to the previous year [4] - Gross profit from proprietary products was $285.7 million, exceeding the average estimate of $257.16 million [4] - Gross profit from contract-manufactured products was reported at $18.2 million, which fell short of the average estimate of $25.76 million [4] Stock Performance - Over the past month, shares of West Pharmaceutical have declined by 10.5%, while the Zacks S&P 500 composite experienced a minor decline of 0.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

West Pharmaceutical Services (NYSE:WST) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Company ParticipantsBob McMahon - CFODan Leonard - Managing Director of Equity ResearchDaniel Markowitz - VPDavid Windley - Managing DirectorDoug Schenkel - Managing DirectorEric Green - CEOJohn Sweeney - VP of Investor RelationsMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director of Equity ResearchConference Call ParticipantsBrendan Smith - Director and Senior AnalystJustin Bowers - Equity Research ...

West Pharmaceutical Services (NYSE:WST) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Company ParticipantsBob McMahon - CFODan Leonard - Managing Director of Equity ResearchDaniel Markowitz - VPDavid Windley - Managing DirectorDoug Schenkel - Managing DirectorEric Green - CEOJohn Sweeney - VP of Investor RelationsMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director of Equity ResearchConference Call ParticipantsBrendan Smith - Director and Senior AnalystJustin Bowers - Equity Research ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $805 million, representing a 7.5% increase on a reported basis and a 3.3% increase organically [8][17] - Adjusted EPS for the fourth quarter was $2.04, up 12% compared to the prior year [8][22] - Free cash flow in the fourth quarter was $175 million, more than double the prior year level, contributing to a full year free cash flow of $469 million, up 70% year-on-year [8][23] Business Segment Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in the fourth quarter and 9% for the full year of 2025 [9][18] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year organically, primarily due to an incentive payment received in the prior year [10][18] - Standard Products, which represent 20% of the business, declined 1.7% on an organic basis during the fourth quarter [10][18] - Contract manufacturing revenues increased 1.9% organically in Q4, driven by self-injected devices for obesity and diabetes [10][18] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, increasing global regulatory requirements, and the expanding GLP-1 market [5][11] - The company has initiated over 700 Annex 1 projects, with over half completed and generating revenues, representing less than 15% of the 6 billion components targeted for upgrades [12][80] Company Strategy and Development Direction - The company aims to leverage growth drivers such as biologics, Annex 1, and GLP-1s to advance its strategies and expects robust momentum entering 2026 [11][17] - The launch of the West Synchrony Prefillable Syringe System is a significant step in drug delivery solutions, designed specifically for biologics [5][72] - The company plans to continue investing in high-value product components while exploring potential technologies for inorganic growth [39][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy, highlighting a strong order book and demand from biologic customers [42][59] - The company anticipates organic revenue growth of 5%-7% and adjusted EPS growth of 10% at the midpoint for 2026 [17][28] - Management remains cautious about GLP-1 growth, projecting a 10% increase year-on-year, which is considered conservative given the previous year's growth of over 50% [26][76] Other Important Information - The company expects to close the SmartDose transaction mid-year, which will impact revenue guidance for 2026 [24][25] - Capital expenditures for 2026 are expected to decrease to a range of $250 million-$275 million, reflecting a focus on efficiency [23][28] Q&A Session Summary Question: Insights on GLP-1 customer demand and guidance conservatism - Management indicated no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength in the overall business beyond GLP-1s [35][36] Question: Potential for share buybacks or M&A - Management confirmed that capital deployment will prioritize organic growth but remains open to technologies that could enhance the HVP components business [39][40] Question: Demand outstripping supply in HVP components - Management acknowledged that demand continues to outpace supply, particularly in the HVP components business, and is actively expanding capacity [42][43] Question: Clarification on new GLP-1 molecules and HVP components - Management noted that new GLP-1 molecules are expected to use similar elastomeric HVP components, with a mix of new combination molecules requiring proprietary technologies [46][49] Question: Progress on Annex 1 upgrades - Management stated that less than 15% of the 6 billion components have been commercialized, with expectations for continued revenue growth from these projects in 2026 [80]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - West Pharmaceutical Services (WST) reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, and showing an increase from $1.82 per share a year ago, resulting in an earnings surprise of +11.21% [1] - The company achieved revenues of $805 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.35% and increasing from $748.8 million year-over-year [2] - West Pharmaceutical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.64, with expected revenues of $759.74 million, while for the current fiscal year, the EPS estimate is $7.67 on revenues of $3.24 billion [7] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Eric M. Green West Pharmaceutical Services, Inc. President & CEO, Chair of the Board Bob W. McMahon Senior VP & Chief Financial Officer Fourth-Quarter and Full-Year 2025 Earnings Call February 12, 2026 | 8 a.m. Eastern Time To participate on the call by asking questions to Management, please register in advance by clicking here. A replay of the webcast will be available on the Company's website for on the call. approximately 90 days after the event. Registered telephone participants will receive the dial-in ...

Exhibit 99.1 West Reports Fourth-Quarter and Full-Year 2025 Results – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – Exton, PA, February 12, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year p ...

Core Insights - West Pharmaceutical is forecasting annual profit above Wall Street estimates following a strong fourth-quarter performance driven by high demand for its proprietary products, including syringes [1] Group 1 - The company reported better-than-expected fourth-quarter results, indicating robust demand for its proprietary products [1] - The forecast for annual profit suggests a positive outlook, exceeding market expectations [1]